JP2006520766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006520766A5 JP2006520766A5 JP2006505151A JP2006505151A JP2006520766A5 JP 2006520766 A5 JP2006520766 A5 JP 2006520766A5 JP 2006505151 A JP2006505151 A JP 2006505151A JP 2006505151 A JP2006505151 A JP 2006505151A JP 2006520766 A5 JP2006520766 A5 JP 2006520766A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- therapeutic treatment
- cancer
- prophylactic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03290728A EP1460076A1 (en) | 2003-03-21 | 2003-03-21 | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| PCT/EP2004/004013 WO2004083210A1 (en) | 2003-03-21 | 2004-03-19 | SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006520766A JP2006520766A (ja) | 2006-09-14 |
| JP2006520766A5 true JP2006520766A5 (enExample) | 2007-05-10 |
| JP4572194B2 JP4572194B2 (ja) | 2010-10-27 |
Family
ID=32799141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505151A Expired - Fee Related JP4572194B2 (ja) | 2003-03-21 | 2004-03-19 | 置換された８−パーフルオロアルキル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7217715B2 (enExample) |
| EP (2) | EP1460076A1 (enExample) |
| JP (1) | JP4572194B2 (enExample) |
| KR (1) | KR101070075B1 (enExample) |
| CN (1) | CN100368412C (enExample) |
| AR (1) | AR053082A1 (enExample) |
| AT (1) | ATE433977T1 (enExample) |
| AU (1) | AU2004222105B2 (enExample) |
| BR (1) | BRPI0408605A (enExample) |
| CA (1) | CA2517774C (enExample) |
| CY (1) | CY1109345T1 (enExample) |
| DE (1) | DE602004021572D1 (enExample) |
| DK (1) | DK1608653T3 (enExample) |
| EA (1) | EA009198B1 (enExample) |
| ES (1) | ES2328812T3 (enExample) |
| IL (1) | IL170634A (enExample) |
| MX (1) | MXPA05010112A (enExample) |
| NO (1) | NO20054331L (enExample) |
| NZ (1) | NZ542224A (enExample) |
| PL (1) | PL1608653T3 (enExample) |
| PT (1) | PT1608653E (enExample) |
| SI (1) | SI1608653T1 (enExample) |
| TW (1) | TWI322809B (enExample) |
| WO (1) | WO2004083210A1 (enExample) |
| ZA (1) | ZA200507192B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| US8771552B2 (en) * | 2005-06-23 | 2014-07-08 | Sumitomo Electric Industries, Ltd. | Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same |
| JP4277826B2 (ja) | 2005-06-23 | 2009-06-10 | 住友電気工業株式会社 | 窒化物結晶、窒化物結晶基板、エピ層付窒化物結晶基板、ならびに半導体デバイスおよびその製造方法 |
| US9708735B2 (en) | 2005-06-23 | 2017-07-18 | Sumitomo Electric Industries, Ltd. | Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| EP1790649A1 (en) * | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP1939187A1 (en) * | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
| EP2138492A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
| EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
| EP2138494A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| EP2138495A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
| EP2138498A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
| SI2448940T1 (sl) | 2009-07-02 | 2014-10-30 | Sanofi | Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba |
| WO2012085244A1 (fr) | 2010-12-23 | 2012-06-28 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001270884A (ja) * | 2000-03-23 | 2001-10-02 | Mitsubishi-Tokyo Pharmaceuticals Inc | ピリミドン誘導体 |
| EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| ATE269333T1 (de) * | 2000-09-01 | 2004-07-15 | Sanofi Synthelabo | 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate |
| EP1184383A1 (en) * | 2000-09-01 | 2002-03-06 | Sanofi-Synthelabo | 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives |
| EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
-
2003
- 2003-03-21 EP EP03290728A patent/EP1460076A1/en not_active Withdrawn
-
2004
- 2004-03-17 TW TW093107078A patent/TWI322809B/zh not_active IP Right Cessation
- 2004-03-19 BR BRPI0408605-8A patent/BRPI0408605A/pt not_active IP Right Cessation
- 2004-03-19 DE DE602004021572T patent/DE602004021572D1/de not_active Expired - Lifetime
- 2004-03-19 AU AU2004222105A patent/AU2004222105B2/en not_active Ceased
- 2004-03-19 CA CA2517774A patent/CA2517774C/en not_active Expired - Fee Related
- 2004-03-19 WO PCT/EP2004/004013 patent/WO2004083210A1/en not_active Ceased
- 2004-03-19 SI SI200431223T patent/SI1608653T1/sl unknown
- 2004-03-19 PT PT04721905T patent/PT1608653E/pt unknown
- 2004-03-19 DK DK04721905T patent/DK1608653T3/da active
- 2004-03-19 NZ NZ542224A patent/NZ542224A/en not_active IP Right Cessation
- 2004-03-19 CN CNB2004800120101A patent/CN100368412C/zh not_active Expired - Fee Related
- 2004-03-19 EP EP04721905A patent/EP1608653B1/en not_active Expired - Lifetime
- 2004-03-19 JP JP2006505151A patent/JP4572194B2/ja not_active Expired - Fee Related
- 2004-03-19 AR ARP040100918A patent/AR053082A1/es unknown
- 2004-03-19 EA EA200501311A patent/EA009198B1/ru not_active IP Right Cessation
- 2004-03-19 MX MXPA05010112A patent/MXPA05010112A/es active IP Right Grant
- 2004-03-19 ZA ZA200507192A patent/ZA200507192B/xx unknown
- 2004-03-19 KR KR1020057017571A patent/KR101070075B1/ko not_active Expired - Fee Related
- 2004-03-19 AT AT04721905T patent/ATE433977T1/de active
- 2004-03-19 ES ES04721905T patent/ES2328812T3/es not_active Expired - Lifetime
- 2004-03-19 PL PL04721905T patent/PL1608653T3/pl unknown
-
2005
- 2005-09-01 IL IL170634A patent/IL170634A/en not_active IP Right Cessation
- 2005-09-13 US US11/224,873 patent/US7217715B2/en not_active Expired - Fee Related
- 2005-09-20 NO NO20054331A patent/NO20054331L/no not_active Application Discontinuation
-
2007
- 2007-04-04 US US11/696,256 patent/US7393853B2/en not_active Expired - Fee Related
-
2009
- 2009-09-02 CY CY20091100926T patent/CY1109345T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006520766A5 (enExample) | ||
| JP2006519814A5 (enExample) | ||
| JP2006520767A5 (enExample) | ||
| WO2007002516A3 (en) | Improved dosage forms for movement disorder treatment | |
| WO2009149486A3 (en) | Compounds for treating beta-amyloidoses | |
| IN2012DN02763A (enExample) | ||
| MX2009004908A (es) | Compuestos quimicos. | |
| EP1717235A3 (en) | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands | |
| JP2007504174A5 (enExample) | ||
| MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
| IL171591A (en) | Quinuclidine derivatives, process for their preparation and use thereof for the manufacture of medicaments for the treatment of conditions mediated by the muscarinic m3 receptor | |
| HK1207860A1 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
| JP2005511597A5 (enExample) | ||
| TW200745135A (en) | Therapeutic agents | |
| MY162902A (en) | Phosphaplatins and their use for treatment of cancers | |
| JP2007516193A5 (enExample) | ||
| JP2006519813A5 (enExample) | ||
| WO2006058869A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| TW200531688A (en) | Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents | |
| IL179160A0 (en) | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | |
| TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture | |
| JP2008526706A5 (enExample) | ||
| MX2010008706A (es) | Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales. | |
| WO2010019911A3 (en) | 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions | |
| WO2014141169A3 (en) | Novel anti-neurodegenerative natural compounds isolated from alpiniae oxyphyllae fructus and total synthesis theirof |